What the FDA’s Recent Peptide Advisory Committee Decision Means for Patients
The world of peptide therapy has changed dramatically over the past several years. Following regulatory uncertainty and restrictions on many commonly prescribed peptides, patients and providers alike have been left navigating a fragmented marketplace with limited access to trusted compounded medications. Last week marked an important step forward. The FDA’s Pharmacy Compounding Advisory Committee (PCAC) […]
What the FDA’s Recent Peptide Advisory Committee Decision Means for Patients Read More »









